Form 4: CONMED Corp CEO Curt R. Hartman Executes Stock Appreciation Rights and Disposes of Shares

Curt R. Hartman, President and CEO of CONMED Corp, exercised stock appreciation rights and disposed of shares on November 7, 2024.

Summary

• On November 7, 2024, Curt R. Hartman, the President and CEO of CONMED Corp, executed stock appreciation rights (SARs) and disposed of common stock.
• Hartman exercised SARs for 30,000 shares at a price of $51.3.
• He also disposed of 24,303 shares of common stock at $74.76.
• Following these transactions, Hartman directly owns 9,996 shares of common stock and indirectly owns 83,500 shares through a trust.
• He also directly owns 118,300 stock appreciation rights.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions, which is neutral in sentiment.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency into the trading activities of CONMED Corp's CEO. Such filings are common and expected in the healthcare industry.

Comparison to Industry Standards

• Executive compensation packages often include stock options and stock appreciation rights to align management's interests with those of shareholders.
• Form 4 filings are standard practice across publicly traded companies, including CONMED's competitors in the medical device industry such as Stryker, Johnson & Johnson, and Medtronic.
• The vesting schedule of the SARs (20% per year over five years) is a common vesting structure.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the overall impact is likely minimal.

Key Dates